Mexico continues to face a significant TB burden, with 37,000 people estimated to have developed the disease in 2023. Alongside TB, co-infections with HIV remain a concern, affecting over 4,200 individuals. Drug-resistant TB further complicates the healthcare response, with more than 1,300 people affected nationwide.
In 2023, we provided CAD4TB to Mexico for research, which will be conducted on a provincial level to assess the potential utilization of CAD4TB in support of TB screening in Mexico.
